$16.24 $0.57 (3.6%)

04:00 PM EST on 11/22/19

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates, with exclusive worldwide commercial rights to three product candidates in clinical development for various central nervous system disorders.

Current Price $16.24 Mkt Cap $835.8M
Open $15.77 P/E Ratio 6.81
Prev. Close $15.67 Div. (Yield) $0.00 (0.0%)
Daily Range $15.73 - $16.26 Volume 418,725
52-Wk Range $11.83 - $31.30 Avg. Daily Vol. 554,848

Caps

How do you think NASDAQ:VNDA will perform against the market?

Add Stock to CAPS Watchlist

All Players

177 Outperform
110 Underperform
 

All-Star Players

32 Outperform
35 Underperform
 

Wall Street

4 Outperform
1 Underperform
 

Top NASDAQ:VNDA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rbitrage (95.53)
Submitted June 23, 2014

Company has an expensive drug approved to treat blind people who are concerned about being on the same 24-hr calendar as the rest of us. Nobody else has a drug a drug like it. The best part is that people who are blind are generally covered by… More

rknapton (78.49)
Submitted August 22, 2013

Short. Pharma company with declining revenues and losses widening.

NASDAQ:VNDA VS S&P 500 (SPY)

Fools bullish on NASDAQ:VNDA are also bullish on:

Fools bearish on NASDAQ:VNDA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VNDA.

Recs

0
Member Avatar TMFBlacknGold (94.01) Submitted: 10/3/2019 11:15:41 AM : Outperform Start Price: $19.90 NASDAQ:VNDA Score: -32.42

From 08/05/2019:

"On the one hand, Vanda Pharmaceuticals appears to be on a promising trajectory with its current drug products. Hetlioz and Fanapt are growing sales and driving operating income growth.

On the other hand, there are certainly red flags waving. The company's spat with the FDA over tradipitant in gastroparesis is an oddly stubborn stance, especially in light of separate ongoing legal issues related to Fanapt and Hetlioz. Vanda Pharmaceuticals should have the financial strength to survive a delay in tradipitant or pay potential fines related to false marketing claims, but investors may not feel comfortable owning the stock. A 40% year-to-date decline in stock price suggests that wouldn't be a minority perspective."

Note: I overlooked the lawsuit related to allegedly violating the Federal False Claims Act in previous writing. Explained that oversight in the article below, but decided to keep this pick open in CAPS.

https://www.fool.com/investing/2019/08/05/vanda-pharmaceuticals-returns-to-profitability-in.aspx

Recs

0
Member Avatar Seth15701 (63.43) Submitted: 2/10/2019 3:38:36 AM : Outperform Start Price: $19.05 NASDAQ:VNDA Score: -29.42

Overreaction to suing the FDA for animal abuse. Earnings next week. This will rebound, bank on it.

Recs

0
Member Avatar LazyHarlequin (95.64) Submitted: 2/6/2019 10:46:51 AM : Underperform Start Price: $20.83 NASDAQ:VNDA Score: +35.96

On 2/6/19 down $4.17 to $20.90.

Leaderboard

Find the members with the highest scoring picks in VNDA.

Score Leader

Loerke

Loerke (56.94) Score: +296.36

The Score Leader is the player with the highest score across all their picks in VNDA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mxh5000 39.93 5/29/2009 Underperform 1Y $14.61 +11.16% +243.73% +232.58 0 Comment
kravlani < 20 5/14/2009 Underperform 3M $12.75 +27.37% +254.16% +226.79 0 Comment
Macademia 74.90 5/26/2009 Underperform 3Y $12.44 +30.55% +255.69% +225.14 0 Comment
OctoStalin 38.33 5/26/2009 Underperform 5Y $12.44 +30.55% +255.69% +225.14 0 Comment
kinikanik 21.69 1/7/2013 Outperform 1Y $3.74 +334.22% +113.22% +221.01 0 Comment
1or5stars 99.79 6/2/2009 Underperform 3W $14.40 +12.78% +232.87% +220.09 0 Comment
BlacknGold2 63.45 10/19/2012 Outperform 5Y $3.74 +334.22% +115.38% +218.84 0 Comment
jm3383 39.40 5/21/2009 Underperform 3M $11.71 +38.69% +253.41% +214.72 0 Comment
numero9 40.41 6/8/2009 Underperform 5Y $13.14 +23.59% +237.00% +213.41 0 Comment
bama136 64.98 6/3/2009 Underperform 1Y $12.74 +27.47% +238.07% +210.60 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VNDA.